Medical and economic impact of extraintestinal infections due to Escherichia coli:: focus on an increasingly important endemic problem

被引:580
作者
Russo, TA
Johnson, JR
机构
[1] SUNY Buffalo, VA Med Ctr, Ctr Microbial Pathogenesis, Dept Med & Microbiol,Div Infect Dis, Buffalo, NY 14214 USA
[2] Univ Minnesota, VA Med Ctr, Dept Med, Minneapolis, MN USA
关键词
extraintestinal Escherichia coli infections; economics; incidence of infection; costs; mortality; antibiotic resistance; sepsis; urinary tract infection;
D O I
10.1016/S1286-4579(03)00049-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Escherichia coli is probably the best-known bacterial species and one of the most frequently isolated organisms from clinical specimens. Despite this, underappreciation and misunderstandings exist among medical professionals and the lay public alike regarding E. coli as an extraintestinal pathogen. Underappreciated features include (i) the wide variety of extraintestinal infections E. coli can cause, (ii) the high incidence and associated morbidity, mortality, and costs of these diverse clinical syndromes, (iii) the pathogenic potential of different groups of E. coli strains for causing intestinal versus extraintestinal disease, and (iv) increasing antimicrobial resistance. In this era in which health news often sensationalizes uncommon infection syndromes or pathogens, the strains of E. coli that cause extraintestinal infection are an increasingly important endemic problem and underappreciated "killers". Billions of health care dollars, millions of work days, and hundreds of thousands of lives are lost each year to extraintestinal infections due to E. coli. New treatments and prevention measures will be needed for improved outcomes and a diminished disease burden. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.
引用
收藏
页码:449 / 456
页数:8
相关论文
共 72 条
[1]   Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[2]  
[Anonymous], 1996, Am J Infect Control, V24, P380
[3]  
[Anonymous], 2000, World Health Report 2000: Health Systems: Improving Performance
[4]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[6]   Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea [J].
Cheong, HJ ;
Yoo, CW ;
Sohn, JW ;
Kim, WJ ;
Kim, MJ ;
Park, SC .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) :48-53
[7]   A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation [J].
Cook, D ;
Guyatt, G ;
Marshall, J ;
Leasa, D ;
Fuller, H ;
Hall, R ;
Peters, S ;
Rutledge, F ;
Griffith, L ;
McLellan, A ;
Wood, G ;
Kirby, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (12) :791-797
[8]  
Craven D E, 1990, Semin Respir Infect, V5, P157
[9]   NOSOCOMIAL PNEUMONIA IN THE MEDICAL AND SURGICAL PATIENT - RISK-FACTORS AND PRIMARY MANAGEMENT [J].
DALNOGARE, AR .
MEDICAL CLINICS OF NORTH AMERICA, 1994, 78 (05) :1081-1090
[10]   ACUTE BACTERIAL-MENINGITIS IN THE NEWBORN [J].
DELOUVOIS, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 34 :61-73